Therefore, the FOXM1–NEK2–UBE2T axis is a molecular vulnerability in 1q+ MM and provides a rationale for isatuximab-based regimens targeting high-risk cytogenetic subgroups. This evidence concerns the gene NEK2 and Miyoshi myopathy.